Clinical trials: Oral Anticoagulants
Venous Thrombosis, Deep Vein Thrombosis
Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer
This is a multicenter, cohort study evaluating an adapted rivaroxaban dose regimen in patients with acute, proximal deep-vein thrombosis (DVT) or acute pulmonary embolism (PE) who concomitantly use a strong cytochrome P450…
- Trial name
- NCT00786422
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 16 sites in Australia, Austria and 7 more
- Volunteers
- 25 people
- Sponsor
- Bayer
Atrial Fibrillation (AF)
Perioperative Anticoagulant Use for Surgery Evaluation -Virtual Visit (PAUSE-Virtual)
The purpose of the PAUSE-Virtual Study is to show that by changing pre-surgery visits with patients taking a blood thinner (direct oral anticoagulant (apixaban, dabigatran, edoxaban, rivaroxaban or warfarin) when the participant…
- Trial name
- PAUSEVirtual (NCT06844227)
- Where
- 10 sites in United States, Canada and 1 more
- Volunteers
- 1,780 people
- Sponsor
- McMaster University
Atrial Fibrillation
Left Atrial Appendage Occlusion Versus New Oral Anticoagulants for Stroke Prevention in Patients With Non-valvular Atrial Fibrillation
We will compare long-term effectiveness and safety in patients with atrial fibrillation treated with left atrial appendage occlusion versus new oral anticoagulants to prevent ischemic stroke from multicenter registry data
- Trial name
- NCT03108872
- Testing
- left atrial appendage occlusion, New oral anticoagulants
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Sejong General Hospital
Cardioembolic Stroke, Anticoagulant Therapy
Keeping Oral o Parental AnticoaguLation in the Acute Phase of Cardioembolic Ischemic Stroke
This is an observational, prospective, multicenter, cohort study in patients with cardioembolic stroke and previous oral or parenteral anticoagulant therapy.
- Conditions
- Cardioembolic Stroke, Anticoagulant Therapy, Stroke Recurrence, Haemorrhagic Transformation Stroke
- Trial name
- KOALA-IS (NCT05486351)
- Testing
- Observation
- Where
- 3 sites in France, Spain
- Volunteers
- 318 people
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
Atrial Fibrillation, Stroke
Anticoagulation in Stent Intervention
Objective: The main objective is to evaluate the pattern of dual antiplatelet therapy (aspirin, 300 mg / day + clopidogrel 75 mg / day) compared to the use of the triple regimen (Acenocoumarol as control + acetylsalicylic acid…
- Trial name
- MUSICA-2 (NCT01141153)
- Testing
- Acetylsalicylic Acid + clopidogrel + acenocoumarol, Acetylsalicylic Acid + clopidogrel
- Where
- 11 sites in Spain
- Volunteers
- 304 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Coronary Artery Disease
Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI
Clopidogrel is the P2Y12 inhibitor of choice in PCI patients requiring OAC. However, concerns have been raised based on the notion that a considerable number of patients may have inadequate response to clopidogrel.
- Trial name
- SWAP-AC-2 (NCT04483583)
- Testing
- Ticagrelor 60mg, Clopidogrel
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- University of Florida
Atrial Fibrillation
AIHEMAF - P "An Innovative Healthcare Model for AF Patients"
Non-profit observational study on the role of the community pharmacist and "the pharmacy of services" in the case management of patients suffering from atrial fibrillation and being treated with new generation oral anticoagulants
- Trial name
- AIHEMAF - P (NCT05086991)
- Testing
- Follow up
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Farmacia La Regina s.r.l.
Oral Anticoagulants, Invasive Procedure
Oral Anticoagulant Peri-procedural Management in Patients Undergoing an Oral Surgery, Implantology or Periodontology
Patients receiving long-term oral anticoagulant (defined as duration of treatment of at least 1 month of Direct Oral Anticoagulant (DAOC) or Vitamin K Antagonist (VKA)) and referred for an invasive procedure (oral surgery…
- Trial name
- PRADICO (NCT03150303)
- Where
- France
- Volunteers
- 532 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Gastrointestinal Bleeding, Cardiovascular Complication
Gastrointestinal Endoscopy in Patients With Prothrombotic Conditions: THE ENDOHEM REGISTRY
This observational study evaluates the safety of gastrointestinal endoscopy in patients on oral anticoagulants (Vitamin K antagonists, rivaroxaban, dabigatran, edoxaban, and apixaban).
- Conditions
- Gastrointestinal Bleeding, Cardiovascular Complication, Anticoagulants; Circulating, Hemorrhagic Disorder, Gastrointestinal Endoscopy
- Trial name
- NCT03669068
- Testing
- Gastrointestinal endoscopy
- Where
- Spain
- Volunteers
- 1,602 people
- Sponsor
- Hospital Universitario Ramon y Cajal
Atrial Fibrillation
Evaluation of Treatment Safety in Patients With Atrial Fibrillation on Edoxaban Therapy in Real-Life in Turkey
This is a national, multi-center, prospective study to evaluate the safety of Edoxaban in patients diagnosed with AF who are currently using Edoxaban for stroke prevention.
- Trial name
- ETAF-TR (NCT04594915)
- Testing
- Edoxaban
- Where
- 45 sites in Turkey (Türkiye)
- Volunteers
- 1,053 people
- Sponsor
- Daiichi Sankyo Turkey, a Daiichi Sankyo Company
Anticoagulants, Influenza Vaccines
Influenza Vaccination and Oral Anticoagulant Therapy
The purpose of this study is to evaluate INR and INR related index and Warfarin weekly dosage variations after Influenza Vaccination
- Trial name
- NCT00222638
- Testing
- Influenza vaccination
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- University Of Perugia
Atrial Fibrillation
Comparative Effectiveness of Oral Anticoagulants
This cohort study plans to identify initiators of oral anticoagulants using electronic claims data from a commercial insurance database to quantify associations between anticoagulant choice (warfarin and dabigatran) and the…
- Trial name
- NCT01847547
- Volunteers
- 5,982 people
- Sponsor
- Boehringer Ingelheim
Anticoagulants and Bleeding Disorders, Surgery
Oral Surgery in Patients Taking Direct Oral Anticoagulants
This study evaluates the incidence of postoperative bleeding after oral surgical procedures in patients taking direct oral anticoagulants and in patients taking vitamin K antagonists.
- Conditions
- Anticoagulants and Bleeding Disorders, Surgery, Postoperative Hemorrhage, Dentoalveolar Haemorrhage
- Trial name
- OSDOA (NCT04505475)
- Testing
- Oral surgical procedure followed by local hemostatic measures (insertion of gelatine sponge and wound suturing)
- Where
- Serbia
- Volunteers
- 82 people
- Sponsor
- University of Novi Sad
Stroke
Study of the Follow-up of Stroke Treated With Anticoagulants
Stroke is a major public health problem as it is very frequent (140,000 cases/year in France), and very serious (leading cause of death, 2nd leading cause of dementia, 3rd leading cause of handicap).
- Trial name
- AOD (NCT03292575)
- Testing
- Anticoagulants
- Where
- France
- Volunteers
- 441 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Intracerebral Hemorrhage
rFVIIa in ICH in Patients Treated With Anticoagulants or Anti-Platelets
Evaluation of efficacy and safety of recombinant factor VIIa versus standard therapy in preventing early haematoma growth in spontaneous acute intracerebral haemorrhage in patients treated with oral anticoagulants or…
- Trial name
- NCT00222625
- Testing
- rFVIIa + (vit K in AO patients), FFP or aPCC+ vit K in AO treated patients
- Where
- 9 sites in Italy
- Volunteers
- 32 people
- Sponsor
- University Of Perugia
Intracerebral Hemorrhage
Treatment of Intracerebral Hemorrhage in Patients on Non-vitamin K Antagonist
Novel, non-vitamin K antagonist oral anticoagulants (NOAC) target selected players in the coagulation cascade as the direct thrombin inhibitor dabigatran and the factor Xa-inhibitors apixaban and rivaroxaban.
- Trial name
- TICH-NOAC (NCT02866838)
- Testing
- Tranexamic acid, Saline 0.9%
- Where
- Switzerland
- Volunteers
- 64 people
- Sponsor
- University Hospital, Basel, Switzerland
Ischemic Stroke, Intracranial Hemorrhages
Novel Oral Anticoagulants in Stroke Patients
The present study will monitor and explore acute neurovascular emergencies in patients treated with NOACs compared to those under treatment with VKAs.
- Trial name
- NOACISP (NCT02353585)
- Where
- Switzerland
- Volunteers
- 1,050 people
- Sponsor
- University Hospital, Basel, Switzerland
Atrial Fibrillation (AF), VTE
Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure
PAUSE 2 study is a prospective, open-label, blinded-endpoint non-inferiority RCT of PAUSE vs. ASRA management in DOAC treated high risk patients with AF/VTE who need elective high bleed risk surgery/procedure and/or any procedure…
- Trial name
- PAUSE 2 RCT (NCT06957366)
- Testing
- PAUSE Perioperative DOAC Management, ASRA Perioperative DOAC Management
- Where
- 14 sites in United States, Belgium and 2 more
- Volunteers
- 920 people
- Sponsor
- McMaster University
Venous Thromboembolism, Active Cancer
Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism
This prospective, multicenter, randomized, open-label, blinded-endpoint trial aims to compare the clinical efficacy and safety of edoxaban-based treatment versus apixaban-based treatment in patients with cancer-associated venous…
- Trial name
- NEXT-CAT (NCT07852637)
- Testing
- edoxaban, Apixaban
- Where
- 12 sites in South Korea
- Volunteers
- 2,300 people
- Sponsor
- Samsung Medical Center
Ischemic Stroke, TIA
Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events
Nondisabling cerebrovascular events represent the largest group of cerebrovascular disease with a high risk of recurrent stroke.
- Trial name
- ADANCE (NCT01924325)
- Testing
- Apixaban, Clopidogrel, Aspirin
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Xijing Hospital